# A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

> **NCT07556549** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer ALK-positive

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT07556549
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-04-22
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07556549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07556549, "A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT07556549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*